Background
==========

Uterine fibroids are benign tumors targeting childbearing women of 30 to 50 years old. Although it is considered a hormone-dependent disease, the causes of uterine fibroids remain unclear \[[@b1-medscimonit-22-4803]\]. Surgical resection is widely used for treatment of uterine fibroids, but surgical resection definitely affects women's health. Non-surgical therapies have not shown satisfactory effects \[[@b2-medscimonit-22-4803],[@b3-medscimonit-22-4803]\]. The rising incidence of uterine fibroids in recent years has triggered studies of the efficacy of various drugs on uterine fibroids and their working mechanisms. Flavonoids became one of the natural substances of interest because they have anti-inflammatory and anti-tumor effects and can be easily found in nature. Flavones and flavonols are two well-known monomers of flavonoids \[[@b4-medscimonit-22-4803]\]. As an important agent with abundant flavonols, kaempferol is the most widely-used drug for the study of uterine fibroids \[[@b5-medscimonit-22-4803]\]. Previous studies showed that kaempferol not only inhibited the proliferation of cancer cells, but also induced apoptosis \[[@b6-medscimonit-22-4803]\]. Moreover, kaempferol was shown to have promising efficacy on multiple cancers \[[@b7-medscimonit-22-4803]\], but it was still unclear how kaempferol influenced uterine fibroids.

Considering the complicated mechanisms underlying the inhibitory effects of drugs on cancer, various biomarkers will be considered in our study. According to previous findings \[[@b4-medscimonit-22-4803]\], we proposed multiple factors might be involved in the efficacy of kaempferol, including ER, VEGF, IGF-1, and myocardin.

In summary, the present study focused on the effect of kaempferol on uterine fibroids *in vitro* to explore biomarkers related to such effects and demonstrate the underlying mechanisms.

Material and Methods
====================

Material
--------

### Tissue collection

Uterine fibroid tissue and surrounding smooth muscle were collected from thirty women with uterine fibroids hospitalized in the Second People's Hospital of Liaocheng who underwent subtotal hysterectomy or total hysterectomy from Oct. 2013 to Oct. 2014. Their average age was 47.7±2.3 years. The study was approved by the medical ethics committee of the Second People's Hospital of Liaocheng. All women participating in this study signed a patient consent form.

Inclusion criteria: Women were included in this study if they 1) were diagnosed with uterine fibroids; 2) without hormone treatment within three months; 3) married; and 4) middle aged (45 to 50 years).

Exclusion criteria: Women were excluded from this study if they 1) were suffering from other gynecological diseases other than uterine fibroids; and 2) were suffering other medical conditions that might affect this study, such as hypertension and diabetes.

### Reagents and instruments

Reagents: High glucose (10%) DMEM medium, 0.25% trypsin, FBS, CDT-FBS, type II collagenase, kaempferol (School of Public Health, Southeast University), PVDF membrane, mouse anti-human smooth muscle actin monoclonal antibodies, BCA protein assay kit, CCK-8 proliferation kit, protein extraction kit, tetrabromoethane buffer, ER antibody, IGF-1 antibody, VEGF antibody, ECL substrate kit, and β-actin monoclonal antibodies. Proteins were detected using horseradish peroxidase (HRP)-labeled goat anti-rabbit and mouse secondary antibodies and protein size markers. β-actin was detected as a loading control.

Instruments: ELISA microplate reader, fluorescence quantitative PCR cycler, UV spectrometer.

Methods
-------

Cell culture \[[@b6-medscimonit-22-4803]\]: After the removal of the uterus, fibroid tissue and neighboring normal tissue (1 cm^3^) were taken by the same operator under sterile condition. Three pieces of tissue were sampled for each case. The tissues were transferred to 50 mL centrifuge tubes with an appropriate amount of type II collagenase and incubated in a 37°C shaker for 2--6 hours until the tissues were completely digested, centrifuged at 1000 rpm for 5 minutes, and supernatant collected. Cells were resuspended with high glucose DMEM with 10% FBS at a density of 5×10^5^ cells/ml and cultured in a 37°C incubator with 5% CO~2~. Trypsin (0.25%) was used to passage the cells at a 1:2 ratio when they reached 90% confluency. Cells at 2--5 generations were used in this study.

Experimental groups: the experimental cells were treated with kaempferol dissolved in absolute ethanol (12 μM, 24 μM, 48 μM) as an intervention. Control cells were treated with absolute ethanol alone.

Real-time quantitative RT-PCR \[[@b8-medscimonit-22-4803]\]: Total RNA of cultured uterine leiomyoma cells was extracted with Trizol. The integrity and purity of the RNA was measured by agarose gel electrophoresis and UV spectrometry. RT-PCR was performed according to kit instructions to produce cDNA. The real-time PCR reaction system was as follows: 10 μL SYBR Green Mix, 10.6 μL primer 1, 20.6 μL primer 2, 2 μL cDNA solution, 6.8 μL H~2~O. The reaction conditions were: 2 minutes 94°C, followed by 35 cycles of 94°C 45 seconds, 56°C 45 seconds, 72°C 45 seconds. The final extension was 72°C, 7 minutes. Primer sequences used in this study are shown in [Table 1](#t1-medscimonit-22-4803){ref-type="table"}.

CCK-8 assay \[[@b9-medscimonit-22-4803]\]: 100 μL of 3--5-generation cells were seeded to three 96-well plates at a density of 2×10^5^/mL. Culture medium was removed after attachment, then 12, 24, or 48 μmol/L of kaempferol was used to treat the cells. Each concentration had 5 replicates. CCK-8 reagent (10 μL) was added to each well 2 hours before the end of the experiment and an ELISA microplate reader was used to read the absorbance at 450 nm. The proliferation index (PI%) was calculated as the average absorbance difference between experimental and control groups divided by the average absorbance of the control group.

Immunoblot \[[@b10-medscimonit-22-4803]\]: equal amounts of protein extract were used for agarose gel electrophoresis according to their concentrations. The gel was soaked in transfer buffer for 10\~20 minutes, and the proteins transferred to a nitrocellulose membrane which was soaked in deionized water for 5 minutes. Ponceau S was used to stain the nitrocellulose membrane and marker pen to mark the protein molecular weight standards. The nitrocellulose membrane was then blocked in 10% skim milk for 2 hours at room temperature. Primary antibody and HRP-conjugated secondary antibody were diluted with 5% nonfat milk and incubated with the membrane for 24 hours at 4°C and 2 hours at room temperature, respectively. The membrane was then exposed, developed, and fixed in a dark room. The protein expression level was quantified with statistical software.

Statistical analysis
--------------------

SPSS13.0 was used for statistical analysis. All data were expressed as mean ±SD. The chi-square test was used for the study of count data. A paired t-test was used for analysis between groups. P\<0.05 was considered significant.

Results
=======

Effects of kaempferol on the proliferation of uterine fibroids
--------------------------------------------------------------

Kaempferol significantly inhibited the proliferation of uterine fibroid cells (P\<0.05). The inhibitory effect was increased with increasing concentration and treatment time of kaempferol and reached a peak at 48 hours ([Table 2](#t2-medscimonit-22-4803){ref-type="table"}).

Effect of kaempferol on the mRNA expression of ER, IGF-1, and VEGF
------------------------------------------------------------------

Kaempferol treatment significantly lowered the mRNA levels of ER, IGF-1, and VEGF. The inhibitory effect of kaempferol on the mRNA levels of ER and IGF-1 was increased with the increase of kaempferol concentration (P\<0.05). However, the inhibitory effect of kaempferol on the mRNA level of VEGF showed no change with the increase of kaempferol concentration (P\>0.05) ([Table 3](#t3-medscimonit-22-4803){ref-type="table"}, [Figure 1](#f1-medscimonit-22-4803){ref-type="fig"}).

Effect of kaempferol on the protein levels of ER, IGF-1, and VEGF
-----------------------------------------------------------------

The effect of kaempferol on the protein levels of ER, IGF-1, and VEGF is shown in [Figure 1](#f1-medscimonit-22-4803){ref-type="fig"}. The protein band density is shown in [Table 4](#t4-medscimonit-22-4803){ref-type="table"}, normalized to the band density of β-actin set to 1. Results indicated that the inhibitory effect of kaempferol on the protein levels of ER, IGF-1, and VEGF was increased with the increase of kaempferol concentration (P\<0.05).

Expression of myocardin in uterine fibroids and its surrounding smooth muscle tissue
------------------------------------------------------------------------------------

Results showed that the expression of myocardin in uterine fibroids is significantly lower than that in surrounding smooth muscle tissue ([Figures 2](#f2-medscimonit-22-4803){ref-type="fig"}, [3](#f3-medscimonit-22-4803){ref-type="fig"}).

Discussion
==========

Uterine fibroids are one of the most common benign tumors of the female reproductive system. They are mainly found in women of reproductive age, and during and after menopause. Androgens, such as methyl testosterone tablets or testosterone propionate injections are widely used clinically as treatment for this condition. However, androgen, if used improperly, can easily cause women's masculinization. Natural active flavonoids (mainly monomers, such as flavones and flavonols) are of high interest for treatment of uterine fibroids, and kaempferol is one of the most broadly studied flavonols with a plant source. Studies have proved that kaempferol effectively inhibits the proliferation of cancer cells including liver cancer, stomach cancer, and cervical cancer. The kaempferol used in this study was extracted and purified from the Chinese herbal medicine Huaijiao (Sophora japonica-Leguminosae). Previous studies showed that there is a positive correlation between the inhibitory effect of kaempferol on cell proliferation and kaempferol concentration \[[@b11-medscimonit-22-4803],[@b12-medscimonit-22-4803]\]. In this study, we showed that cell proliferation varied with time of treatment and concentration, showing that kaempferol has an inhibitory effect on uterine fibroid cell proliferation and this inhibition is positively correlated with kaempferol concentration.

Previous studies showed that the inhibitory effect of kaempferol on tumor cell proliferation may be due to its induction of tumor cell apoptosis \[[@b13-medscimonit-22-4803]--[@b15-medscimonit-22-4803]\]. This study showed that kaempferol significantly lowered the levels of both mRNA and protein of ER, IGF-1, and VEGF. Estrogen not only promotes normal uterine smooth muscle cell mitosis, but also inhibits apoptosis of uterine fibroids. IGF-1 is one of the mediators of estrogen4\[[@b16-medscimonit-22-4803]\], and has positive effects on the development of uterine fibroids. VEGF could promote ECM deposition to stimulate the growth of uterine fibroids. The experimental results showed that kaempferol treatment inhibited ER, IGF-1, and VEGF at both mRNA and protein levels, and thats suppression of ER, IGF-1, and VEGF increased with the increase of kaempferol concentration (P\<0.05). The results indicated that kaempferol treatment not only inhibited the proliferation of human uterine fibroid cells *in vitro*, but also reduced the expression of ER, IGF-1, and VEGF at both mRNA and protein levels. The effect of kaempferol on apoptosis of human uterine fibroid cells is currently not known and needs to be further explored.

Previous studies showed that that the level of estrogen receptors (ER) in uterine fibroids is higher than in normal smooth muscle tissue, and mifepristone showed good therapeutic effect clinically, indicating that estrogen has a great influence on the development of uterine fibroids. IGF-1 has been shown to promote the growth of tumors through induction of mitogenesis. Myocardin is one of the key factors for the differentiation of cardiac and smooth muscle cells with the cooperation of SRF-CArG \[[@b17-medscimonit-22-4803],[@b18-medscimonit-22-4803]\]. Myocardin not only exists in the cardiac muscle cells, but is also present in arteries, bladder tissue, intestinal tissue (both small intestine and colon), and uterus, among other tissues. In addition, it also exists in human normal muscle tissue and female uterine fibroids, suggesting that myocardin is involved in the occurrence and development of uterine fibroids. Therefore, detection of myocardin, ER, IGF-1, and VEGF can help explain the effect of kaempferol on the proliferation of uterine fibroids cells. Kaempferol can inhibit smooth muscle cell proliferation, so that the expression of uterine fibroid marker genes is suppressed. This leads to changes in cell structure and cell shape, loss of contractile functions, and abnormal cell proliferation. It is known that myocardin is a major cofactor of the SRF transcription factor and plays a very important role in the differentiation of smooth muscle cells \[[@b19-medscimonit-22-4803],[@b20-medscimonit-22-4803]\]. This study also showed that the level of myocardin in uterine fibroids was significantly lower than that of smooth muscle tissue. Kaempferol treatment significantly lowered the level of myocardin in uterine fibroids.

Conclusions
===========

Kaempferol can suppress the proliferation of uterine fibroid cells, lower the levels of ER, IGF-1, VEGF, and myocardin *in vitro*. Kaempferol has inhibitory effects on fertility, but it can be used for treating uterine fibroids in patients without fertility requirements and menopausal women.
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###### 

Primer sequences for RT-PCR.

  ---------------------------------------------------------
  mRNA    DNA sequences                       PCR product
  ------- ----------------------------------- -------------
  ER      F 5′-TGCCAAGGAGACTCGCTAG-3′\        249bp
          R 5′-CCTCTTCGTCTTTTCGTATCC-3′       

  IGF-1   F 5′-GCTGGTGGATGCTCTTCAGTTC-3′\     184bp
          R 5′-AGCTGACTTGGCAGGCTTGAG-3′       

  VEGF    F 5′-GCAGAATCATCATCACGAAGTGGT-3′\   253bp
          R 5′-TGAAGATGTACTCGATCTCATCA-3′     
  ---------------------------------------------------------

###### 

Effects of kaempferol on the proliferation of uterine fibroids.

  Group              24 h                                                                                                                                                                          48 h   72 h                                                                                                                                                                                                                                                                                                                                                              
  ------------------ ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------ ------------------------------------------------------------------------------------------------------------------------ ------ --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------
  Control            0.857±0.051                                                                                                                                                                   --     0.872±0.055                                                                                                              --     0.916±0.028                                                                                                                                                                                                                       --
  Kaempferol group                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
   12 μml/L          0.867±0.033[\*](#tfn1-medscimonit-22-4803){ref-type="table-fn"}                                                                                                               89.7   0.659±0.052[\*](#tfn1-medscimonit-22-4803){ref-type="table-fn"},[&](#tfn4-medscimonit-22-4803){ref-type="table-fn"}      75.7   0.762±0.059[\*](#tfn1-medscimonit-22-4803){ref-type="table-fn"},[&](#tfn4-medscimonit-22-4803){ref-type="table-fn"},[@](#tfn5-medscimonit-22-4803){ref-type="table-fn"}                                                           83\. 4
   24 μml/L          0.657±0.038[\*](#tfn1-medscimonit-22-4803){ref-type="table-fn"},[\*\*](#tfn2-medscimonit-22-4803){ref-type="table-fn"}                                                        78.1   0.622±0.029[\*](#tfn1-medscimonit-22-4803){ref-type="table-fn"},[&](#tfn4-medscimonit-22-4803){ref-type="table-fn"}      72.4   0.690±0.035[\*](#tfn1-medscimonit-22-4803){ref-type="table-fn"},[\*\*](#tfn2-medscimonit-22-4803){ref-type="table-fn"},[@](#tfn5-medscimonit-22-4803){ref-type="table-fn"}                                                        75\. 6
   48 μml/L          0.549±0.051[\*](#tfn1-medscimonit-22-4803){ref-type="table-fn"},[\*\*](#tfn2-medscimonit-22-4803){ref-type="table-fn"},[\#](#tfn3-medscimonit-22-4803){ref-type="table-fn"}   64.5   0.603±0.023[\*](#tfn1-medscimonit-22-4803){ref-type="table-fn"},[\*\*](#tfn2-medscimonit-22-4803){ref-type="table-fn"}   68.3   0.619±0.034[\*](#tfn1-medscimonit-22-4803){ref-type="table-fn"},[\*\*](#tfn2-medscimonit-22-4803){ref-type="table-fn"},[\#](#tfn3-medscimonit-22-4803){ref-type="table-fn"},[@](#tfn5-medscimonit-22-4803){ref-type="table-fn"}   68\. 4

Compared to control group, P\<0.05;

Compared to the group of 12 μmol/L with the same treatment time, P\<0.05;

Compared to the group of 24 μmol/L with the same treatment time, P\<0. 05;

Compared to the group of 24 hours treatment, P\<0.05;

Compared to the group of 24 hours treatment, P\<0.05.

###### 

Effect of kaempferol on the mRNA expression of ER, IGF-1, and VEGF.

  Group              ER mRNA                                                                                                                                                                       IGF-1 mRNA                                                                                                               VEGF mRNA
  ------------------ ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------ ---------------------------------------------------------------------------------------------------------------------
  Control            1.273±0.026                                                                                                                                                                   1.046±0.028                                                                                                              1.283±0.016
  Kaempferol group                                                                                                                                                                                                                                                                                                          
   12 μml/L          1.036±0.013[\*](#tfn6-medscimonit-22-4803){ref-type="table-fn"}                                                                                                               0.916±0.026                                                                                                              0.847±0.062[\*](#tfn6-medscimonit-22-4803){ref-type="table-fn"},[&](#tfn9-medscimonit-22-4803){ref-type="table-fn"}
   24 μml/L          0.845±0.050[\*](#tfn6-medscimonit-22-4803){ref-type="table-fn"}                                                                                                               0.733±0.060[\*](#tfn6-medscimonit-22-4803){ref-type="table-fn"},[\*\*](#tfn7-medscimonit-22-4803){ref-type="table-fn"}   0.745±0.034[\*](#tfn6-medscimonit-22-4803){ref-type="table-fn"},[&](#tfn9-medscimonit-22-4803){ref-type="table-fn"}
   48 μml/L          0.712±0.053[\*](#tfn6-medscimonit-22-4803){ref-type="table-fn"},[\*\*](#tfn7-medscimonit-22-4803){ref-type="table-fn"},[\#](#tfn8-medscimonit-22-4803){ref-type="table-fn"}   0.651±0.013[\*](#tfn6-medscimonit-22-4803){ref-type="table-fn"},[\*\*](#tfn7-medscimonit-22-4803){ref-type="table-fn"}   0.733±0.045[\*](#tfn6-medscimonit-22-4803){ref-type="table-fn"},[&](#tfn9-medscimonit-22-4803){ref-type="table-fn"}

Compared to control group, P\<0.05;

Compared to 12 μmol/L group, P\<0.05;

Compared to 24 μmol/L group, P\<0.05;

No significant difference between groups of different concentrations of kaempferol, P\>0.05.

###### 

Effect of kaempferol on the protein levels of ER, IGF-1, and VEGF.

  Protein   Control   12 μml/L                                                           24 μml/L                                                                                                                   48 μml/L
  --------- --------- ------------------------------------------------------------------ -------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  VEGF      1         0.735±0.055[\*](#tfn10-medscimonit-22-4803){ref-type="table-fn"}   0.626±0.036[\*](#tfn10-medscimonit-22-4803){ref-type="table-fn"}                                                           0.396±0.033[\*](#tfn10-medscimonit-22-4803){ref-type="table-fn"},[\*\*](#tfn11-medscimonit-22-4803){ref-type="table-fn"},[\#](#tfn12-medscimonit-22-4803){ref-type="table-fn"}
  IGF       1         0.615±0.064[\*](#tfn10-medscimonit-22-4803){ref-type="table-fn"}   0.464±0.055[\*](#tfn10-medscimonit-22-4803){ref-type="table-fn"},[\*\*](#tfn11-medscimonit-22-4803){ref-type="table-fn"}   0.203±0.025[\*](#tfn10-medscimonit-22-4803){ref-type="table-fn"},[\*\*](#tfn11-medscimonit-22-4803){ref-type="table-fn"},[\#](#tfn12-medscimonit-22-4803){ref-type="table-fn"}
  ER        1         0.926±0.047[\*](#tfn10-medscimonit-22-4803){ref-type="table-fn"}   0.876±0.012[\*](#tfn10-medscimonit-22-4803){ref-type="table-fn"}                                                           0.624±0.066[\*](#tfn10-medscimonit-22-4803){ref-type="table-fn"},[\*\*](#tfn11-medscimonit-22-4803){ref-type="table-fn"}
  β-actin   1         1                                                                  1                                                                                                                          1

Compared to control group, P\<0.05;

Compared to 12 μmol/L group, P\<0.05;

Compared to 24μmol/L group, P\<0.05.
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